ArticleInternational journal of molecular sciences2026
Loss of TIMM8A Inhibits Breast Cancer Progression Through Promoting HSPA9 Ubiquitination and Degradation via Competitive Interaction with RNF4.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
To investigate the role and underlying mechanisms of TIMM8A in breast cancer progression. The expression of TIMM8A in breast cancer tissues and cell lines was assessed. Functional assays were performed to evaluate the effects of TIMM8A knockdown on proliferation, metastasis, and apoptosis in BT549 and MCF-7 cells. Co-immunoprecipitation (Co-IP) and ubiquitination assays were used to examine the interaction between TIMM8A and HSPA9, as well as the involvement of the E3 ubiquitin ligase RNF4. PI3K/AKT pathway activity was assessed by Western blotting. In vivo tumor growth was evaluated using a xenograft mouse model. TIMM8A was significantly upregulated in breast cancer tissues and cell lines, and high TIMM8A expression correlated with poor prognosis. TIMM8A knockdown suppressed proliferation and metastasis while inducing apoptosis in vitro. Mechanistically, TIMM8A interacted with HSPA9 and maintained its protein stability by inhibiting RNF4-mediated ubiquitination and degradation, thereby sustaining PI3K/AKT signaling activation. Conversely, TIMM8A depletion reduced HSPA9 stability and attenuated the pathway. Rescue experiments confirmed that HSPA9 overexpression restored PI3K/AKT activation and reversed TIMM8A-knockdown-induced malignant suppression. In vivo, TIMM8A silencing efficiently inhibited tumor growth, accompanied by reduced HSPA9 and Ki-67 expression and decreased PI3K/AKT phosphorylation. TIMM8A promotes breast cancer progression through the TIMM8A/HSPA9/PI3K/AKT regulatory axis, highlighting TIMM8A as a promising prognostic biomarker and potential therapeutic target for breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.